Biosensis is involved in the development and supply of biological reagents and assay kits for research and diagnostic applications, including ELISA assays and antibodies.

Biosensis

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Metric
Company Name	Biosensis	Clinuvel Pharmaceuticals Limited
Symbol		CUV
MSH ID	COM:BIOSENSIS	COM:CLINUVEL
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	AU	AU
Stage
Employee Count		16
Website	biosensis.com	clinuvel.com
LinkedIn
Founders

Metric
Market Cap		481.89M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		56.34M
Revenue (LTM)
Revenue (NTM)
Gross Profit		49.90M
EBITDA		35.96M
Operating Income		35.23M
Net Income		22.77M
EPS		0.45
Diluted EPS		0.44
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.76
Operating Profit Margin		0.53
EBITDA Margin		0.64
Net Profit Margin		0.41
Return on Equity		0.19
Return on Assets		0.15
Return on Capital Employed		0.22

COM:BIOSENSIS

Biosensis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		26.62
P/B Ratio		4.95
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		10.72
EV Multiple		22.57

Metric
Days Sales Outstanding		103.53
Days Payables Outstanding		135.48
Days Inventory Outstanding		188.05
Operating Cycle		297.33
Cash Conversion Cycle		255.83
Asset Turnover		0.38

Metric
Operating Cash Flow		23.68M
Free Cash Flow		20.11M
Cash Flow to Debt		118.80
Operating Cash Flow/Sales		0.52
Free Cash Flow Yield		0.05

Metric
Cash & Equivalents		117.49M
Accounts Receivable		-2.57M
Inventory		6.79M
Goodwill
Debt to Capitalization		0.01
Debt to Assets		0.01
Current Ratio		7.44
Quick Ratio		8.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.11
R&D to Revenue		0.02
SG&A to Revenue		0.02